Introduction
Lennox-Gastaut syndrome (LGS) is a medically intractable epilepsy syndrome characterized by various types of seizures, generalized slow spike and wave discharges and paroxysmal fast activity on electroencephalograms (EEG), and psychomotor retardation. 1, 2 Seizures in LGS patients are usually refractory to multiple antiepileptic treatments, and patients suffer from frequent disabling seizures and adverse effects from polypharmaceutical treatment. The practical goal of treating LGS patients is to reduce the seizure frequency and to prevent seizure-related physical trauma. The efficacy of some antiepileptic drugs (AEDs) such as lamotrigine, felbamate, and topiramate as adjuvant therapies to reduce the seizure frequency in LGS patients has been proven. [3] [4] [5] However, these AEDs have limitations in that they control only some types of seizures. No novel drug has effectively controlled all types of seizures in LGS patients. 6, 7 Rufinamide is a triazole derivative that is structurally distinct from other antiepileptic agents. Randomized controlled trials have proven the efficacy and safety of adjuvant rufinamide therapy over a placebo in LGS patients. 8, 9 In this study, we evaluated the efficacy of rufinamide as an adjuvant treatment according to different seizure types in children with LGS.
Patients and methods

Subjects
Children and adolescents younger than 20 years of age were eligible for the study if they had been diagnosed with LGS and had experienced four or more convulsive seizures and several other types of seizures in the previous month.
LGS was diagnosed when the patient had an EEG pattern typical of LGS, which includes generalized slow sharp and wave discharges and generalized Purpose: To evaluate the efficacy of rufinamide as an add-on treatment in children and adolescents with Lennox-Gastaut syndrome (LGS). Methods: The study was an open-label, observational clinical trial of rufinamide as an add-on treatment in intractable LGS patients. This intent-to-treat trial included 4 weeks of scheduled titrated doses and a 12-week maintenance phase with a target dose of 20-40 mg/kg rufinamide, adjusted according to its effectiveness and tolerability after a baseline period of 4 weeks. The primary outcome was measured by the seizure-reduction rate according to individual seizure type over the 12-week maintenance period. Results: One hundred and twenty-eight patients with LGS who were determined to be unresponsive to one or more antiepileptic drugs or dietary therapy were enrolled. Of the 128 patients enrolled, 112 (87.5%) completed the study. After add-on rufinamide treatment, 46 patients (35.9%) achieved a more than 50% reduction in seizure frequency and 10 (7.8%) patients became seizure-free. When we identified those who responded with an at least 50% reduction in seizure frequency, 39.4% of the responders reported reductions in convulsive seizures, 36.4% in drop attacks, 33.3% in myoclonic seizures, and 20.0% in epileptic spasms. Overall, 32.8% of patients reported adverse effects, which were mostly mild and transient in nature. The most common adverse effects were fatigue (15 patients, 11.7%) and poor appetite (9 patients, 7.0%). Twenty-one (16.4%) patients experienced an increased seizure frequency.
Conclusions: Rufinamide appears to be a safe and effective adjuvant treatment for many cases of intractable LGS.
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paroxysmal fast activity, along with at least two types of seizures such as convulsive (tonic, clonic, and tonic-clonic), drop attack (tonic-atonic or atonic seizure), myoclonic, epileptic spasms, or atypical absence, confirmed by a routine EEG or video EEG monitoring including non-rapid eye movement sleep within the most recent six months. Patients were excluded if there was evidence of a progressive cerebral lesion or neurodegenerative metabolic disorder, or if the patients experienced less than four pre-existing convulsive seizures in the one-month baseline period. During the evaluation period, patients who were treated with other AEDs, except for short-acting intravenous benzodiazepine for rescue from prolonged seizures, were also excluded. All of the patients were first divided into a cryptogenic group and a symptomatic group. Patients who had developed neurologic dysfunction before seizure onset and showed any abnormalities on neuroimaging or dysmorphic features through an extensive genetic and metabolic work-up were assigned to the symptomatic group. The symptomatic group was again sub-classified, according to the cause of LGS, into four groups, ''malformation of cortical development,'' ''destructive encephalopathy,'' ''metabolic causes,'' and ''unknown etiology.'' Metabolic causes were assigned only to those patients with a diagnosis confirmed through specific biochemical or pathological methods. Among the symptomatic groups, those who had no specific abnormal features based on extensive etiological evaluation were assigned to the unknown etiology group. In comparison to the symptomatic group, the cryptogenic group included patients with no abnormal neurological signs or preceding developmental delay before seizure onset, who were clearly distinct from the unknown etiology group due to the absence of any abnormal structural or biochemical features based on neuroimaging, genetic, and metabolic evaluations.
The study was conducted at two referral hospitals offering pediatric epilepsy care. The protocol was approved by the institutional review boards of both study centers. Informed consent was obtained from all participants and their guardians.
Study design
This intent-to-treat study was an open-label, observational clinical trial of rufinamide as an add-on treatment in intractable LGS patients with no allocation of patients to a placebo group. A prospective baseline phase of one month was used to assess seizure frequency according to individual seizure type. The 16-week treatment period included an initial 4 weeks of titration and 12 weeks of maintenance. Following the screening, titration was started at 10 mg/kg/day and was increased by 5-10 mg/kg every 1-2 weeks to achieve a maintenance dosage of 20-40 mg/kg/day with a fixed dose escalation. The target dose was modified according to the patient's tolerability and the treatment efficacy (Fig. 1A ).
Outcome measures
Throughout the trial, patients or their guardians maintained diaries to record the type and frequency of seizures as well as possible adverse effects. At each hospital visit, the investigator reviewed the patient's seizure diary. Patient visits were scheduled at 4, 8, 12, and 16 weeks. All efficacy analyses were based on the intent-to-treat population, who were given rufinamide. Seizures were classified into five groups: convulsive (tonic, clonic, and tonic-clonic), any type of drop attack, myoclonic, epileptic spasms, and atypical absence, according to the guidelines of the International League Against Epilepsy (ILAE). 10 A drop attack was defined as a tonic-atonic or atonic seizure because of the practical difficulties for the parents to differentiate tonic from tonic-atonic seizures that cause the patients to fall. Seizure outcome was evaluated based on the reduction in the rate of each of the five seizure types that the parents reported most frequently. Seizure frequency changes were classified as ''seizure free,'' ''greater than 75% decrease,'' ''50-75% decrease,'' ''less than 50% decrease,'' ''no change,'' or ''worsening of seizures,'' relative to the baseline values. In patients with atypical absence seizures, the response was evaluated as ''worthwhile improvement'' or ''persisting'' due to the difficulty in determining the frequency of the seizures of this type. The percentage of patients with a more than 50% reduction in seizure frequency was also assessed, and was defined as the responder rate. We calculated the percentage of change in seizure frequencies in all patients after a 12-week treatment with rufinamide compared with the baseline seizure frequency according to seizure type. The tolerability and safety of rufinamide were monitored throughout the trial by neurological and physical examinations that took the patient's weight, vital signs, and evaluation of treatment-related adverse effects into account (one visit during the baseline period and four subsequent visits during the 12-week trial). Clinical laboratory evaluations including a complete blood count, aspartate aminotransferase/ alanine aminotransferase assays, and electrocardiography were performed at the initial phase and at the end of the study. The incidence of treatment-related adverse events was also assessed.
Statistical methods
The efficacy parameter of interest was the seizure reduction rate during the treatment period. The intent-to-treat (ITT) population for the efficacy analyses included all patients who received at least one dose of rufinamide and who underwent at least one efficacy evaluation during treatment. Statistical analysis of nonparametric measures was conducted using SAS version 9.2 (Statistical Analysis System Institute, Cary, NC, USA). The level of significance was set to P < 0.05.
Results
Subject characteristics
Of the 128 patients with LGS, 85 were boys and 43 were girls with a mean age of 9.4 AE 4.7 years (1.8-19.9 years). The duration of previous AED treatment was 6.6 AE 4.7 years. The clinical and demographic characteristics of the patients are listed in Table 1 . Rufinamide was started at 10 mg/kg/day and titrated weekly with a 5-10 mg/kg increase every 1-2 weeks for 4 weeks. The final maintenance dose was 31.7 AE 8.7 mg/kg/day. At the time of rufinamide treatment initiation, all patients were receiving an average of 3.3 (range, 1-6) concomitant AEDs; 18 patients (14.1%) were on a ketogenic (n = 16) or modified Atkins diet (n = 2), and three patients had been implanted with a vagal nerve stimulation device. The most commonly used concomitant AEDs were valproate (n = 81, 63.3%), lamotrigine (n = 57, 44.5%), benzodiazepines (n = 53, 41.4%), levetiracetam (n = 51, 39.8%), and zonisamide (n = 50, 39.1%). During maintenance, all other AEDs, including dietary interventions and vagal nerve stimulation parameters, were maintained in the same manner as during the baseline period.
Efficacy
Among the 128 patients treated with rufinamide, 112 patients (87.5%) were retained after 12 weeks (Fig. 1B) . The causes of premature discontinuation of rufinamide included inadequate seizure control in 11 patients (8.6%), adverse effects in 4 patients (3.1%), and loss to follow-up of 1 patient (0.8%). The overall seizure reduction rate was 31.7%. Rufinamide reduced the seizure frequency by 100% (seizure freedom) in 7.8% of patients (n = 10), more than 75% in 18.0% of patients (n = 23), 50-75% in 10.2% of patients (n = 13), and by less than 50% in 8.6% of patients (n = 11). However, 39.1% (n = 50) of patients experienced no change in seizure frequency, and 16.4% (n = 21) reported a more than 25% increase in seizure frequency. Patients with a greater than 50% reduction in seizure frequency were defined as responders. The clinical efficacy according to seizure type is summarized in Table 2 . The highest responder rate of 39.4% (n = 28) was observed in the convulsive seizure group, followed by the drop attack group (36.5%), myoclonic seizure group (33.3%), and epileptic spasm group (20%). Twenty percent of patients with atypical absence seizures reported ''worthwhile improvement'' in seizure frequency. Among ten patients who became seizure-free after rufinamide adjuvant treatment, six (60.0%) had convulsive seizures, three had drop attacks, and only one had epileptic spasms as the main seizure type. When we analyzed the correlation between efficacy and AED combination, including the ketogenic diet, we did not detect a significant synergistic effect from rufinamide (t-test, P > 0.05).
Safety
Adverse effects were reported in 32.8% patients (n = 42). Profiles of adverse effects are shown in Table 3 . The most commonly reported adverse effects were fatigue in 15 patients, poor appetite in 9 patients, as well as somnolence, rash, hyperactivity, poor quality of sleep, and vomiting, in order of frequency. Adverse effects leading to premature discontinuation of rufinamide were fatigue, vomiting, menorrhagia, and eye blinking, with each being found in one patient, for a total of four patients being withdrawn from the study; all of these symptoms resolved spontaneously after discontinuing treatment. None of the adverse effects resulted in permanent health problems.
Discussion
The results of this study show that rufinamide as an add-on therapy in pediatric patients with LGS is both effective and safe. We found that 7.8% (10 of 128 patients) of patients became seizure-free and 35.9% (46 of 128 patients) experienced a more than 50% reduction in disabling seizures with rufinamide medication. The overall seizure reduction rate was 31.7%. This is consistent with the 32.7% median seizure reduction rate reported in 74 rufinamide-treated patients in a randomized, controlled, double-blind trial by Glauser et al. 8 and the 41.0% responder rate in total seizures reported for LGS patients over a period of 12 months by Kluger et al. 9 Among the five seizure types, patients with convulsive seizures and drop attacks benefited the most from rufinamide treatment. Considering that convulsive seizures and drop attacks are the most commonly reported disabling seizure types (104, 81.3%) within this population, rufinamide is an effective adjuvant therapy in controlling the seizures that have the greatest impact on the quality of life for LGS patients. Drop attacks were the second most common disabling seizure type in our study group, and the responder rate in this group was 36.4%. This finding is comparable to the 42.5% reduction in the frequency of tonic-atonic seizures (drop attacks), compared to a placebo group reported by Glauser et al. 9 Rufinamide appears to be better than topiramate at controlling drop attacks; a previous study reported that only 28% of drop-attack patients were topiramate responders (n = 13/46).
5
There are few reports on the efficacy of rufinamide in patients with epileptic spasms. Olson et al. 11 reported a responder rate of 53% after rufinamide add-on therapy in 38 patients with epileptic spasms with or without hypsarrhythmia. In this study, we observed a 20.0% responder rate in ten patients experiencing epileptic spasms with LGS. The difference in the number of patients between the two studies could be responsible for such a difference in the responder rates. Considering that there are very limited treatment options available for epileptic spasms, rufinamide can be considered an effective adjuvant treatment based on our findings. There were no significant differences in the efficacy of rufinamide according to seizure etiology. The responder rates for patients with a malformation of cortical development (MCD) or cryptogenic etiology were not significantly different (P = 0.173), although rufinamide showed the best efficacy in MCD patients, with a responder rate of 42.9% for any seizure type. This response rate is higher than that observed for patients with a cryptogenic etiology (29.6%), which was regarded as a favorable factor in terms of the ability to control seizures. Further investigations of longer duration in a larger population are necessary to validate the differences we observed in rufinamide efficacy between the etiological groups.
In our study, rufinamide was well-tolerated and safely maintained for 12 weeks after titration, with a retention rate of 87.5% (n = 112). Adverse effects were reported in 32.8% of patients, and all adverse effects were of mild to moderate severity. Frequent adverse effects were similar to those reported in previous studies, 8, 9, 12, 13 namely fatigue, poor appetite, somnolence, rash, and hyperactivity. A patient reported menorrhagia during rufinamide maintenance for ten weeks, which has not been reported previously. The relationship between rufinamide and menorrhagia is not clear. The patient with this AE was a 16-year-old female in menarche, and no other abnormal causative findings of menorrhagia were revealed through a gynecological evaluation. While eye blinking has not been reported in previous reports, diplopia was reported in 19.9% of rufinamide patients, compared to 3.2% of placebo patients, 14 which could represent eye blinking in severely retarded patients. Rufinamide treatment was discontinued in 8 of 128 (6.2%) patients within 12 weeks due to a worsening of seizure frequency, and 21 of 128 patients (16.4%) experienced a worsening of seizure frequency or intensity. This rate is somewhat higher than the 13% reported in patients with childhood epileptic encephalopathy in the study by Coppola et al. 15 However, we were not able to determine the factors related to the development of adverse effects due to limited study duration and patient number.
The results of this study should be considered while keeping in mind the fact that the study was not double-blinded and lacked a placebo arm. Moreover, the short duration of the trial cannot guarantee the long-term results of rufinamide treatment. In conclusion, rufinamide adjuvant treatment appears to be effective, safe, and well-tolerated in patients with LGS. Our findings suggest that rufinamide can provide a considerable benefit in controlling various types of seizures in LGS patients.
